News

Neurotherapeutic Program Aims to Improve Motor, Cognitive Functions

MindMaze is partnering with Mount Sinai Health System in New York to accelerate the access of people with neurological diseases to a pioneer digital neurotherapeutic program to improve patients’ motor and cognitive functions. The program aims to provide high-dose and high-intensity training to improve the brain’s ability…

Cholesterol Med Fails to Slow Disease Progression

Treatment with simvastatin, a medication used to lower cholesterol levels, did not slow the progression of Parkinson’s disease  over a two-year period, according to published data from a Phase 2 trial. Overall, the data provide “no evidence to support proceeding to a phase 3 trial,” the researchers wrote, noting…

Aggression Aimed at Caregivers in Parkinson’s Linked to Patients’ Grief

Aggression aimed at caregivers in Parkinson’s disease and related disorders is associated with patients’ grief in coping with disease progression and related losses, a new study suggests. Fluctuations in cognition also play a role, researchers say. But these behavioral disturbances have serious consequences for caregivers, according to investigators, who…

Phase 2 Trial Supports DopaFuse for Levodopa-carbidopa Oral Delivery

Treatment with DopaFuse, a continuous oral levodopa-carbidopa delivery system being developed by SynAgile, was safe and lessened motor complications in people with Parkinson’s disease, according to results from a Phase 2 clinical trial. “These results suggest that the DopaFuse [levodopa-carbidopa] delivery system can provide a safe, non-invasive…

Dental Care Often Irregular But Needed With Parkinson’s: Study

Dental care often is irregular in people with Parkinson’s disease, who also require more dental treatments that those without this disease, a study from Denmark reported. High-quality initiatives addressing basic care, from daily oral cleanings to regular checkups that could reduce cavities and tooth extractions, are needed for better…

COVID-19 Might Increase Risk for Neurodegenerative Disease

People who had COVID-19 might have an increased risk for developing neurodegenerative diseases, such as Parkinson’s disease, researchers in Australia found. Moreover, the researchers have offered a possible treatment to reduce the  COVID-induced neuroinflammation. COVID-19 activates an inflammatory response in the brain that is similar to Parkinson’s disease, contributing…